Literature DB >> 21414769

Kuguacin J isolated from Momordica charantia leaves inhibits P-glycoprotein (ABCB1)-mediated multidrug resistance.

Pornsiri Pitchakarn1, Shinobu Ohnuma, Komsak Pintha, Wilart Pompimon, Suresh V Ambudkar, Pornngarm Limtrakul.   

Abstract

Multidrug resistance (MDR) is a major factor in the failure of chemotherapy in cancer patients. Resistance to chemotherapy has been correlated to the overexpression of ABC drug transporters including P-glycoprotein (P-gp) that actively efflux chemotherapeutic drugs from cancer cells. Our previous study showed that bitter melon (Momordica charantia) leaf extract (BMLE) was able to reverse the MDR phenotype by increasing the intracellular accumulation of chemotherapeutic drugs. In the present study, bioguided fractionation was used to identify the active component(s) of BMLE that is able to modulate the function of P-gp and the MDR phenotype in a human cervical carcinoma cell line (KB-V1). We found that kuguacin J, one of the active components in BMLE, increased sensitivity to vinblastine and paclitaxel in KB-V1 cells. A flow cytometry assay indicated that kuguacin J inhibits the transport function of P-gp and thereby significantly increases the accumulation of rhodamine 123 and calcein AM in the cells. These results were confirmed by [³H]-vinblastine transport assay. Kuguacin J significantly increases intracellular [³H]-vinblastine accumulation and decreased the [³H]-vinblastine efflux in the cells. Kuguacin J also inhibited the incorporation of [¹²⁵I]-iodoarylazidoprazosin into P-gp in a concentration-dependent manner, indicating that kuguacin J directly interacts with the drug-substrate-binding site on P-gp. These results indicate that kuguacin J modulates the function of P-gp by directly interacting at the drug-substrate-binding site, and it appears to be an effective inhibitor of P-gp activity in vitro and thus could be developed as an effective chemosensitizer to treat multidrug-resistant cancers.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21414769      PMCID: PMC3394403          DOI: 10.1016/j.jnutbio.2010.11.005

Source DB:  PubMed          Journal:  J Nutr Biochem        ISSN: 0955-2863            Impact factor:   6.048


  35 in total

1.  Induction of tumor cytotoxic immune cells using a protein from the bitter melon (Momordica charantia).

Authors:  J E Cunnick; K Sakamoto; S K Chapes; G W Fortner; D J Takemoto
Journal:  Cell Immunol       Date:  1990-04-01       Impact factor: 4.868

Review 2.  Bitter melon (Momordica charantia): a review of efficacy and safety.

Authors:  Ethan Basch; Steven Gabardi; Catherine Ulbricht
Journal:  Am J Health Syst Pharm       Date:  2003-02-15       Impact factor: 2.637

Review 3.  Multidrug resistance transporters and modulation.

Authors:  B Tan; D Piwnica-Worms; L Ratner
Journal:  Curr Opin Oncol       Date:  2000-09       Impact factor: 3.645

4.  Hypoglycemic activity of the fruit of the Momordica charantia in type 2 diabetic mice.

Authors:  T Miura; C Itoh; N Iwamoto; M Kato; M Kawai; S R Park; I Suzuki
Journal:  J Nutr Sci Vitaminol (Tokyo)       Date:  2001-10       Impact factor: 2.000

5.  MAP 30: a new inhibitor of HIV-1 infection and replication.

Authors:  S Lee-Huang; P L Huang; P L Nara; H C Chen; H F Kung; P Huang; H I Huang; P L Huang
Journal:  FEBS Lett       Date:  1990-10-15       Impact factor: 4.124

6.  Effects of bitter melon (Momordica charantia l.) or ginger rhizome (Zingiber offifinale rosc) on spontaneous mammary tumorigenesis in SHN mice.

Authors:  Hiroshi Nagasawa; Katsuto Watanabe; Hideo Inatomi
Journal:  Am J Chin Med       Date:  2002       Impact factor: 4.667

7.  Allosteric modulation of human P-glycoprotein. Inhibition of transport by preventing substrate translocation and dissociation.

Authors:  Nazli Maki; Peter Hafkemeyer; Saibal Dey
Journal:  J Biol Chem       Date:  2003-03-17       Impact factor: 5.157

8.  Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder.

Authors:  W Chearwae; S Anuchapreeda; K Nandigama; S V Ambudkar; P Limtrakul
Journal:  Biochem Pharmacol       Date:  2004-11-15       Impact factor: 5.858

9.  Cancer preventive potential of Momordica charantia L. against benzo(a)pyrene induced fore-stomach tumourigenesis in murine model system.

Authors:  Gagan Deep; Trisha Dasgupta; A R Rao; R K Kale
Journal:  Indian J Exp Biol       Date:  2004-03       Impact factor: 0.818

Review 10.  P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement.

Authors:  Manthena V S Varma; Yasvanth Ashokraj; Chinmoy S Dey; Ramesh Panchagnula
Journal:  Pharmacol Res       Date:  2003-10       Impact factor: 7.658

View more
  11 in total

1.  Kuguacin J isolated from bitter melon leaves modulates paclitaxel sensitivity in drug-resistant human ovarian cancer cells.

Authors:  Pornsiri Pitchakarn; Sonthaya Umsumarng; Sariya Mapoung; Pisamai Ting; Piya Temviriyanukul; Wanisa Punfa; Wilart Pompimon; Pornngarm Limtrakul
Journal:  J Nat Med       Date:  2017-06-21       Impact factor: 2.343

Review 2.  Bitter melon: a panacea for inflammation and cancer.

Authors:  Prasad R Dandawate; Dharmalingam Subramaniam; Subhash B Padhye; Shrikant Anant
Journal:  Chin J Nat Med       Date:  2016-02

3.  Synthetic Analogs of Curcumin Modulate the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCG2.

Authors:  Megumi Murakami; Shinobu Ohnuma; Michihiro Fukuda; Eduardo E Chufan; Katsuyoshi Kudoh; Keigo Kanehara; Norihiko Sugisawa; Masaharu Ishida; Takeshi Naitoh; Hiroyuki Shibata; Yoshiharu Iwabuchi; Suresh V Ambudkar; Michiaki Unno
Journal:  Drug Metab Dispos       Date:  2017-09-13       Impact factor: 3.922

Review 4.  Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy.

Authors:  Komal Raina; Dileep Kumar; Rajesh Agarwal
Journal:  Semin Cancer Biol       Date:  2016-07-21       Impact factor: 15.707

5.  Glycogen Synthase Kinase 3β Inhibitor (2'Z,3'E)-6-Bromo-indirubin- 3'-Oxime Enhances Drug Resistance to 5-Fluorouracil Chemotherapy in Colon Cancer Cells.

Authors:  Kun-Ping Liu; Feng Luo; Si-Ming Xie; Li-Juan Tang; Mei-Xiang Chen; Xue-Fang Wu; Xue-Yun Zhong; Tong Zhao
Journal:  Chin J Cancer Res       Date:  2012-06       Impact factor: 5.087

Review 6.  Targeting AMPK signaling in combating ovarian cancers: opportunities and challenges.

Authors:  Mingo M H Yung; Hextan Y S Ngan; David W Chan
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2016-01-12       Impact factor: 3.848

7.  Enhancement of cellular uptake and cytotoxicity of curcumin-loaded PLGA nanoparticles by conjugation with anti-P-glycoprotein in drug resistance cancer cells.

Authors:  Wanisa Punfa; Supachai Yodkeeree; Pornsiri Pitchakarn; Chadarat Ampasavate; Pornngarm Limtrakul
Journal:  Acta Pharmacol Sin       Date:  2012-05-14       Impact factor: 6.150

8.  Antibacterial and Antiproliferative Activities of Plumericin, an Iridoid Isolated from Momordica charantia Vine.

Authors:  Jutamas Saengsai; Sumonthip Kongtunjanphuk; Nuttawan Yoswatthana; Tanawan Kummalue; Weena Jiratchariyakul
Journal:  Evid Based Complement Alternat Med       Date:  2015-04-07       Impact factor: 2.629

Review 9.  Recent Advances in Momordica charantia: Functional Components and Biological Activities.

Authors:  Shuo Jia; Mingyue Shen; Fan Zhang; Jianhua Xie
Journal:  Int J Mol Sci       Date:  2017-11-28       Impact factor: 5.923

10.  Physician Attitudes and Perceptions of Complementary and Alternative Medicine (CAM): A Multicentre Italian Study.

Authors:  Massimiliano Berretta; Luca Rinaldi; Rosaria Taibi; Paolo Tralongo; Alberto Fulvi; Vincenzo Montesarchio; Giordano Madeddu; Paolo Magistri; Sabrina Bimonte; Marco Trovò; Patrizia Gnagnarella; Arturo Cuomo; Marco Cascella; Arben Lleshi; Guglielmo Nasti; Sergio Facchini; Francesco Fiorica; Raffaele Di Francia; Giuseppe Nunnari; Giovanni Francesco Pellicanò; Aurelio Guglielmino; Marco Danova; Sabrina Rossetti; Alfonso Amore; Anna Crispo; Gaetano Facchini
Journal:  Front Oncol       Date:  2020-04-28       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.